Forgot Password

Thank you for your request!

We will soon reach out to you.

Thank you for downloading..!

Contact us for more information.
Home » Healthcare » Biotechnology » HBI-2031115
  • Global Central Nervous System (CNS) Biomarkers Market Insights, Opportunity, Analysis, Market Shares And Forecast 2017 – 2023

  • Publish: March 2017 | Report Code: HBI-2031115

* For discount/customization and buying a particular chapter click here or write to us at sales@occamsresearch.com

The Global Central Nervous System (CNS) biomarkers market is expected to grow at 10.4% CAGR during the forecast period 2016-2023. A biomarker is a biological feature that is used to measure the biological state, presence of diseases or the effects of treatment. It helps in understanding various chronic diseases, its effects on exposure to certain environmental conditions and also in identification of people who are at high risk of developing the same disease being diagnosed. The demand for CNS biomarker has increased with the development in proteomics, genomics and imaging system, which is a major drivers of the Global Central Nervous System Biomarkers Market. The global CNS biomarker market is witnessing a moderate to high growth in the recent years and is expected to continue so on in the near future. The central nervous system (CNS) biomarkers market is primarily driven by following factors:

  • Development of proteomics, genomics and imaging system Funding from government and private players
  • Increase in life style oriented diseases
  • Increase in public-private partnership
  • FDA approvals
  • Technological advancement Innovation
  • Global increase in healthcare expenditure







The key driver of the global CNS biomarkers market is increasing number of CVD patients. For example according to world health organization 8.8 million people died of cancer, in 2015. Also there were more than 191 million people suffering from chronic diseases in America in 2015. The increasing number of cancer patients and other cardiovascular diseases are fiving a rise to the need of CNS biomarkers. The major factors driving the CNS biomarker market are support from private players and government for increased research and development, development of genomics and imaging system, rapidly increasing geriatric population and increased public private partnerships. As per Administration for Community Living, population aged 65 and above is estimated to reach more than 80 million by 2050, which is twice of that estimated in 2012. This growth of geriatric population is leading to increased development of many diseases like Parkinson’s, Alzheimer’s and multiple sclerosis. As per the Aging Research Centre, approximately 24 million people are affected with Alzheimer’s disease globally. Governments are supporting and funding private and public laboratories to overcome this research and development program across the country. In addition, technological advancements and innovations, development of new applications areas, increasing lifestyle oriented diseases etc. are few factors which are likely to spur the demand of global CNS biomarker market.

 

Source: OBRC Analysis

The global central nervous system biomarkers market is segmented into type, application and end user. Type is further sub segmented into:

  • Safety biomarkers,
  • Efficacy biomarker
  • Predictive biomarker
  • Pharmacodynamic biomarker
  • Prognostic biomarker
  • Validation biomarker.







Application is further segmented into:

  • Diagnostic development
  • Drug discovery and development
  • Personalized medicine
  • Disease risk assessment
  • Other






End-user is further segmented into:

  • Hospitals
  • Eye Clinics
  • Diagnostic Centres
  • Patients





The report scope is widely categorized on the basis of its application and type which include Safety biomarkers, efficacy biomarker, predictive biomarker, pharmacodynamic biomarker, prognostic biomarker and validation biomarker. Moreover, the market revenue estimates and forecast include hospitals, diagnostic centres, patients and eye-clinic.

Geographically, the global central nervous system biomarkers market is segmented into:

  • North America (U.S. & Canada)
  • Asia Pacific (China, India, Japan, RoAPAC)
  • Europe (UK, France, Germany, RoE)
  • Rest of World





Asia Pacific is anticipated to be one the fastest growing CNS markets in global CNS biomarkers market. The major reason for this high growth is wide customer base, improvement in healthcare infrastructure, purchasing power of buyers and increasing government initiatives. However at present, North America has the largest market share in global CNS biomarker marker because in the region healthcare infrastructure is more advanced than any other and also because of increasing geriatric population. For instance, according to the U.S. Census Bureau approximately 20% of the U.S. population is projected to be 65 years and above by 2030.

The global central nervous system biomarkers market is segmented on the basis of type, applications and end users. On the basis of type the market is segmented into safety biomarkers, efficacy biomarkers, predictive biomarkers, pharmacodynamic biomarkers, prognostic biomarkers and validation biomarkers. Application is sub segmented into diagnostic development, drug discovery and development, personalized medicine market, disease risk assessment market and other market.  In the application segment personalized medicine market is expected to have a significant growth due to its increasing demand by patients. The end-user industry segments comprises of hospitals, eye clinics, diagnostic centres and patients.

The major market players of the global central nervous system biomarkers market are:

  • ABIANT INC.,
  • ACUMEN PHARMACEUTICALS INC.,
  • ALSERES PHARMACEUTICALS INC.,
  • APITOPE INTERNATIONAL,
  • APOSENSE, AVACTA GROUP PLC
  • BANYAN BIOMARKERS
  • DIAGENIC ASA
  • OTHERS









Detailed analysis of these companies provided in this report comprises of overview, SCOT analysis, product portfolio, strategic initiative and strategic analysis.

Expansions, mergers & acquisition and collaborations for product development are the key strategies adopted by the market players to sustain in the market also companies are applying for patents for any new product they develop. In January 2016, D Banyan Biomarkers entered into an agreement with Philips to develop and commercialize hand held blood test to evaluate and detect concussions. With this collaboration Banyan Biomarkers was able utilize its knowledge of bio molecules responsible for neurological injuries and take an advantage of Philips’ strength in handheld diagnostic and patient monitoring technologies.

Why to buy the report:

This report will:

  • Provide you the business strategies adopted by market players such as partnership as in January 2016, D Banyan Biomarkers entered into an agreement with Philips.
  • Provide in detail the different segments such as application and end-users which affect the global central nervous system biomarkers market.
  • Provide you the patent analysis of the global central nervous system biomarkers market.
  • Identify and understand the strengths, opportunities, challenges and threats of the central nervous system biomarkers market.
  • Provide revenues of major players of global central nervous system biomarkers market.
  • Provide you the various regulatory policies which affect the global central nervous system biomarkers market.







How we are different from others:

At Occams we provide an extensive portfolio which is comprehensive market analysis along with the market size, market share, and market segmentations. Our report on global central nervous system biomarkers market offers the longest chain of market segmentation based on application, type and end-users. The report tracks the major market trend in the global central nervous system biomarkers market. For each market segments covered in global central nervous system biomarkers market report we provide opportunity matrix, and DROC analysis, that enable the clear growth assessment across each market segment. The report discusses competitive landscape of the global central nervous system biomarkers market, with giving extensive strategy analysis of more than 15 companies. Moreover, the report discusses various models such as 360 degree analysis, See Saw analysis, and Porter five force models and so on. For the high level analysis in the report we provide a comparative analysis of historic and current year data. 

Key findings of the global central nervous system (CNS) biomarkers market.

  • North America accounted the largest revenue share in 2016.
  • Application segment is expected to contribute highest growth of the CNS biomarkers market.
  • Increase in healthcare spending and government favourable policies are creating huge opportunities for the global CNS biomarkers market.
1. INTRODUCTION
1.1. EXECUTIVE SUMMARY
1.2. ESTIMATION METHODOLOGY
 
2. MARKET OVERVIEW
2.1. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET: EVOLUTION & TRANSITION
2.2. MARKET DEFINITION & SCOPE
2.3. INDUSTRY STRUCTURE
2.4. REGULATORY FRAMEWORK
2.5. TOTAL MARKET ANALYSIS
2.5.1. TOP 5 FINDINGS
2.5.2. TOP 5 OPPORTUNITY MARKETS
2.5.3. TOP 5 COMPANIES
2.5.4. TOP 3 COMPETITIVE STRATEGIES
2.6. ESTIMATION ANALYSIS
2.7. STRATEGIC ANALYSIS
2.7.1. INVESTMENT VS. ADOPTION MODEL
2.7.2. 360 DEGREE INDUSTRY ANALYSIS
2.7.3. PORTERS 5 FORCE MODEL
2.7.4. SEE-SAW ANALYSIS
2.7.5. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
2.8. COMPETITIVE ANALYSIS
2.8.1. KEY STRATEGIES & ANALYSIS
2.8.2. MARKET SHARE ANALYSIS
2.8.3. TOP COMPANY ANALYSIS
2.9. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
2.9.1. INVESTMENT OPPORTUNITIES BY REGIONS
2.9.2. OPPORTUNITIES IN EMERGING APPLICATIONS
2.9.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT
 
3. MARKET DETERMINANTS 
3.1. MARKET DRIVERS
3.1.1.  DEVELOPMENT IN PROTEOMICS, GENOMICS AND IMAGING SYSTEM 
3.1.2. FUNDING FROM GOVERNMENT AND PRIVATE PLAYERS
3.1.3. GROWTH IN LIFE STYLE ORIENTED DISEASES
3.1.4. GROWTH IN GOVERNMENT AND PRIVATE FUNDING 
3.1.5. GROWTH IN PUBLIC-PRIVATE PARTNERSHIP
3.1.6. FDA APPROVALS 
3.1.7. TECHNOLOGICAL ADVANCEMENT 
3.1.8. INCREASING INNOVATION 
3.1.9. GLOBAL INCREASE IN HEALTHCARE EXPENDITURE
 
3.2. MARKET RESTRAINTS
3.2.1. HIGH COST OF CNS BIOMARKERMTEST AND DIAGNOSTICS
3.2.2. REIMBURSEMENT ISSUES AFFECTING THE CNS BIOMARKER MARKET
3.3. MARKET OPPORTUNITIES
3.3.1. INCREASING ADOPTION OF PERSONALIZED MEDICINES
3.3.2. UNTAPPED APAC REGION 
3.3.3. GLOBAL INCREASE IN GERIATRIC POPULATION 
3.3.4. FAVORABLE GOVERNMENT POLICIES AND SUPPORT FOR CNS BIOMARKERS
3.4.  MARKET CHALLENGES 
3.4.1. CREATING AWARENESS FOR CNS BIOMARKER MARKET
3.4.2. GLOBAL ECONOMIC SLOWDOWN 
3.4.3. TECHNICAL ISSUES OF SAMPLE COLLECTION AND STORAGE
 
4. MARKET SEGMENTATION 
4.1. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET BY APPLICATION
4.1.1. MARKET DEFINITION AND SCOPE
4.1.2. DECISION SUPPORT 
4.1.3. DATABASE & ESTIMATION METHODOLOGY
4.1.4. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.1.5. OPPORTUNITY MATRIX
4.1.6. MARKET SEGMENTATION 
4.1.6.1. GLOBAL DIAGNOSTIC DEVELOPMENT MARKET
4.1.6.1.1. APPLICATION
4.1.6.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.6.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.6.1.4. TOP PLAYERS & KEY PRODUCTS 
4.1.6.1.5. KEY CONCLUSIONS
4.1.6.2. GLOBAL DRUG DISCOVERY AND DEVELOPMENT MARKET
4.1.6.2.1. APPLICATION
4.1.6.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.6.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.6.2.4. TOP PLAYERS & KEY PRODUCTS 
4.1.6.2.5. KEY CONCLUSIONS
4.1.6.3. GLOBAL PERSONALIZED MEDICINE MARKET
4.1.6.3.1. APPLICATION
4.1.6.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.6.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.6.3.4. TOP PLAYERS & KEY PRODUCTS 
4.1.6.3.5. KEY CONCLUSIONS
4.1.6.4. GLOBAL DISEASE RISK ASSESSMENT MARKET
4.1.6.4.1. APPLICATION
4.1.6.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.6.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.6.4.4. TOP PLAYERS & KEY PRODUCTS 
4.1.6.4.5. KEY CONCLUSIONS
4.1.6.5. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET BY  OTHER 
4.1.6.5.1. APPLICATION
4.1.6.5.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.6.5.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.6.5.4. TOP PLAYERS & KEY PRODUCTS 
4.1.6.5.5. KEY CONCLUSIONS
 
4.2. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET BY TYPE
4.2.1. MARKET DEFINITION AND SCOPE
4.2.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.2.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.2.4. OPPORTUNITY MATRIX
4.2.5. MARKET SEGMENTATION 
4.2.5.1. GLOBAL SAFETY BIOMARKER MARKET
4.2.5.1.1. APPLICATION
4.2.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.1.4. TOP PLAYERS & KEY PRODUCTS 
4.2.5.1.5. KEY CONCLUSIONS
4.2.5.2. GLOBAL EFFICACY BIOMARKER MARKET
4.2.5.2.1. APPLICATION
4.2.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.2.4. TOP PLAYERS & KEY PRODUCTS 
4.2.5.2.5. KEY CONCLUSIONS
4.2.5.3. GLOBAL PREDICTIVE BIOMARKER MARKET
4.2.5.3.1. APPLICATION
4.2.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.3.4. TOP PLAYERS & KEY PRODUCTS 
4.2.5.3.5. KEY CONCLUSIONS
4.2.5.4. GLOBAL PHARMACODYNAMIC BIOMARKER MARKET
4.2.5.4.1. APPLICATION
4.2.5.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.4.4. TOP PLAYERS & KEY PRODUCTS 
4.2.5.4.5. KEY CONCLUSIONS
4.2.5.5. GLOBAL PROGNOSTIC BIOMARKER MARKET
4.2.5.5.1. APPLICATION
4.2.5.5.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.5.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.5.4. TOP PLAYERS & KEY PRODUCTS 
4.2.5.5.5. KEY CONCLUSIONS
4.2.5.6. GLOBAL VALIDATION BIOMARKER MARKET
4.2.5.6.1. APPLICATION
4.2.5.6.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.6.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.6.4. TOP PLAYERS & KEY PRODUCTS 
4.2.5.6.5. KEY CONCLUSIONS
4.3. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET BY   END USERS
4.3.1. MARKET DEFINITION AND SCOPE
4.3.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.3.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.3.4. OPPORTUNITY MATRIX
4.3.5. MARKET SEGMENTATION 
4.3.5.1. GLOBAL HOSPITALS MARKET
4.3.5.1.1. APPLICATION
4.3.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.1.4. TOP PLAYERS & KEY PRODUCTS 
4.3.5.1.5. KEY CONCLUSIONS
4.3.5.2. GLOBAL EYE CLINICS MARKET
4.3.5.2.1. APPLICATION
4.3.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.2.4. TOP PLAYERS & KEY PRODUCTS 
4.3.5.2.5. KEY CONCLUSIONS
4.3.5.3. GLOBAL DIAGNOSTIC CENTERS MARKET
4.3.5.3.1. APPLICATION
4.3.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.3.4. TOP PLAYERS & KEY PRODUCTS 
4.3.5.3.5. KEY CONCLUSIONS
4.3.5.4. GLOBAL PATIENTS MARKET
4.3.5.4.1. APPLICATION
4.3.5.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.4.4. TOP PLAYERS & KEY PRODUCTS 
4.3.5.4.5. KEY CONCLUSIONS
 
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.1.1. LIST OF MERGERS & ACQUISITION 
5.1.2. LIST OF JOINT VENTURES
5.1.3. LIST OF PRODUCT LAUNCHES
5.1.4. LIST OF PARTNERSHIPS
5.2. TOP 10 COMPANY ANALYSIS
 
6. GEOGRAPHICAL ANALYSIS
6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
6.3. OPPORTUNITY MATRIX
6.4. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET BY REGION 
6.4.1. NORTH AMERICA
6.4.1.1. INDUSTRIAL END-USER ANALYSIS 2014-2023 ($ MILLION)
6.4.1.2. TOP COUNTRY ANALYSIS
6.4.1.2.1. U.S. 
6.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.1.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.1.2.1.3. KEY CONCLUSIONS
6.4.1.2.2. CANADA
6.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.1.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.1.2.2.3. KEY CONCLUSIONS
6.4.2. EUROPE
6.4.2.1. INDUSTRY END-USER ANALYSIS 2014-2023 ($ MILLION)
6.4.2.2. TOP COUNTRY ANALYSIS
6.4.2.2.1. UK
6.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.1.3. KEY CONCLUSIONS
6.4.2.2.2. FRANCE
6.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.2.3. KEY CONCLUSIONS
6.4.2.2.3. GERMANY
6.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.3.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.3.3. KEY CONCLUSIONS
6.4.2.2.4. SPAIN
6.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.4.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.4.3. KEY CONCLUSIONS
6.4.2.2.5. REST OF EUROPE
6.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.5.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.5.3. KEY CONCLUSIONS
6.4.3. ASIA PACIFIC
6.4.3.1. INDUSTRY END-USER ANALYSIS 2014-2023 ($ MILLION)
6.4.3.2. TOP COUNTRY ANALYSIS
6.4.3.2.1. CHINA
6.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.1.3. KEY CONCLUSIONS
6.4.3.2.2. INDIA
6.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.2.3. KEY CONCLUSIONS
6.4.3.2.3. JAPAN
6.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.3.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.3.3. KEY CONCLUSIONS
6.4.3.2.4. AUSTRALIA
6.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.4.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.4.3. KEY CONCLUSIONS
6.4.3.2.5. REST OF ASIA PACIFIC
6.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.5.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.5.3. KEY CONCLUSIONS
6.4.4. ROW
6.4.4.1. INDUSTRY END-USER ANALYSIS 2014-2023 ($ MILLION)
6.4.4.2. TOP COUNTRY ANALYSIS
6.4.4.2.1. LATIN AMERICA
6.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.4.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.1.3. KEY CONCLUSIONS
6.4.4.2.2. MIDDLE EAST & AFRICA 
6.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.4.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.2.3. KEY CONCLUSIONS
 
7. COMPANY PROFILES
7.1. ABASTAR MDX INC
7.1.1. OVERVIEW
7.1.2. PRODUCT PORTFOLIO
7.1.3. KEY INNOVATION SECTOR
7.1.4. STRATEGIC INITIATIVES 
7.1.5. SCOT ANALYSIS
7.1.6. STRATEGIC ANALYSIS
7.2. ABIANT INC
7.2.1. OVERVIEW
7.2.2. PRODUCT PORTFOLIO
7.2.3. KEY INNOVATION SECTOR
7.2.4. STRATEGIC INITIATIVES 
7.2.5. SCOT ANALYSIS 
7.2.6. STRATEGIC ANALYSIS
7.3. ACUMEN PHARMACEUTICALS INC
7.3.1. OVERVIEW
7.3.2. PRODUCT PORTFOLIO
7.3.3. KEY INNOVATION SECTOR
7.3.4. STRATEGIC INITIATIVES 
7.3.5. SCOT ANALYSIS
7.3.6. STRATEGIC ANALYSIS
7.4. . ADLYFE INC
7.4.1. OVERVIEW
7.4.2. PRODUCT PORTFOLIO
7.4.3. KEY INNOVATION SECTOR
7.4.4. STRATEGIC INITIATIVES 
7.4.5. SCOT ANALYSIS
7.4.6. STRATEGIC ANALYSIS
7.5. ALSERES PHARMACEUTICALS INC
7.5.1. OVERVIEW
7.5.2. PRODUCT PORTFOLIO
7.5.3. KEY INNOVATION SECTOR
7.5.4. STRATEGIC INITIATIVES 
7.5.5. SCOT ANALYSIS 
7.5.6. STRATEGIC ANALYSIS
7.6. APITOPE INTERNATIONAL.
7.6.1. OVERVIEW
7.6.2. PRODUCT PORTFOLIO
7.6.3. KEY INNOVATION SECTOR
7.6.4. STRATEGIC INITIATIVES 
7.6.5. SCOT ANALYSIS 
7.6.6. STRATEGIC ANALYSIS
7.7.  APOSENSE
7.7.1. OVERVIEW
7.7.2. PRODUCT PORTFOLIO
7.7.3. KEY INNOVATION SECTOR
7.7.4. STRATEGIC INITIATIVES 
7.7.5. SCOT ANALYSIS 
7.7.6. STRATEGIC ANALYSIS
7.8. APPLIED  NEUROSOLUTIONS INC
7.8.1. OVERVIEW
7.8.2. PRODUCT PORTFOLIO
7.8.3. KEY INNOVATION SECTOR
7.8.4. STRATEGIC INITIATIVES 
7.8.5. SCOT ANALYSIS 
7.8.6. STRATEGIC ANALYSIS
7.9. A AVACTA GROUP PLC
7.9.1. OVERVIEW
7.9.2. PRODUCT PORTFOLIO
7.9.3. KEY INNOVATION SECTOR
7.9.4. STRATEGIC INITIATIVES 
7.9.5. SCOT ANALYSIS 
7.9.6. STRATEGIC ANALYSIS
7.10. AVID RADIOPHARMACEUTICALS INC
7.10.1. OVERVIEW
7.10.2. PRODUCT PORTFOLIO
7.10.3. KEY INNOVATION SECTOR
7.10.4. STRATEGIC INITIATIVES 
7.10.5. SCOT ANALYSIS
7.10.6. STRATEGIC ANALYSIS
7.11. BANYAN BIOMARKERS
7.11.1. OVERVIEW
7.11.2. PRODUCT PORTFOLIO
7.11.3. KEY INNOVATION SECTOR
7.11.4. STRATEGIC INITIATIVES 
7.11.5. SCOT ANALYSIS
7.11.6. STRATEGIC ANALYSIS
7.12. DIAGENIC ASA
7.12.1. OVERVIEW
7.12.2. PRODUCT PORTFOLIO
7.12.3. KEY INNOVATION SECTOR
7.12.4. STRATEGIC INITIATIVES 
7.12.5. SCOT ANALYSIS
7.12.6. STRATEGIC ANALYSIS
7.13. EKFDIAGNOSTICS HOLDINGS INC
7.13.1. OVERVIEW
7.13.2. PRODUCT PORTFOLIO
7.13.3. KEY INNOVATION SECTOR
7.13.4. STRATEGIC INITIATIVES 
7.13.5. SCOT ANALYSIS
7.13.6. STRATEGIC ANALYSIS
7.14. ENZO BIOCHEM INC
7.14.1. OVERVIEW
7.14.2. PRODUCT PORTFOLIO
7.14.3. KEY INNOVATION SECTOR
7.14.4. STRATEGIC INITIATIVES 
7.14.5. SCOT ANALYSIS
7.14.6. STRATEGIC ANALYSIS
7.15. EXONHIT THERAPEUTICS
7.15.1. OVERVIEW
7.15.2. PRODUCT PORTFOLIO
7.15.3. KEY INNOVATION SECTOR
7.15.4. STRATEGIC INITIATIVES 
7.15.5. SCOT ANALYSIS
7.15.6. STRATEGIC ANALYSIS
 
LIST OF TABLES
 
1. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET BY  APPLICATION,  2014-2023 ($ MILLION)
2. GLOBAL DIAGNOSTIC DEVELOPMENT MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
3. GLOBAL DRUG DISCOVERY AND DEVELOPMENT MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
4. GLOBAL PERSONALIZED MEDICINE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
5. GLOBAL DISEASE RISK ASSESSMENT MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
6. GLOBAL OTHERS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
7. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET BY  TYPE 2014-2023 ($ MILLION)
8. GLOBAL SAFETY BIOMARKER MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
9. GLOBAL EFFICACY BIOMARKER MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
10. GLOBAL PREDICTIVE BIOMARKER MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
11. GLOBAL VALIDATION BIOMARKER MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
12. GLOBAL PHARMACODYNAMIC BIOMARKER MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
13. GLOBAL PROGNOSTIC BIOMARKER MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
14. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET BY  END USERS 2014-2023 ($ MILLION)
15. GLOBAL HOSPITALS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
16. GLOBAL EYE CLINICS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
17. GLOBAL DIAGNOSTIC CENTERS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
18. GLOBAL PATIENTS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
19. NORTH AMERICA CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET 2014-2023 ($ MILLION)
20. EUROPE CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET 2014-2023 ($ MILLION)
21. ASIA PACIFIC CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET 2014-2023 ($ MILLION)
22. REST OF THE WORLD CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET 2014-2023 ($ MILLION)
 
LIST OF FIGURES
 
1. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET BY  DIAGNOSTIC DEVELOPMENT 2014-2023 ($ MILLION)
2. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET BY  DRUG DISCOVERY AND DEVELOPMENT 2014-2023 ($ MILLION)
3. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET BY  PERSONALIZED MEDICINE 2014-2023 ($ MILLION)
4. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET BY  DISEASE RISK ASSESSMENT 2014-2023 ($ MILLION)
5. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET BY OTHERS 2014-2023 ($ MILLION)
6. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS BY SAFETY BIOMARKER 2014-2023 ($ MILLION)
7. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS BY EFFICACY BIOMARKER 2014-2023 ($ MILLION)
8. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS BY PREDICTIVE BIOMARKER 2014-2023 ($ MILLION)
9. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS BY VALIDATION BIOMARKER 2014-2023 ($ MILLION)
10. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS BY PHARMACODYNAMIC BIOMARKER 2014-2023 ($ MILLION)
11. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS BY PROGNOSTIC BIOMARKER 2014-2023 ($ MILLION)
12. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS BY HOSPITALS 2014-2023 ($ MILLION)
13. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS BY EYE CLINICS 2014-2023 ($ MILLION)
14. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS BY DIAGNOSTIC CENTERS 2014-2023 ($ MILLION)
15. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS BY PATIENTS 2014-2023 ($ MILLION)
16. UNITED STATES (U.S.) CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET 2014-2023 ($ MILLION)
17. CANADA CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET 2014-2023 ($ MILLION)
18. UNITED KINGDOM (UK) CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET 2014-2023 ($ MILLION)
19. FRANCE CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET 2014-2023 ($ MILLION)
20. GERMANY CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET 2014-2023 ($ MILLION)
21. SPAIN CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET 2014-2023 ($ MILLION)
22. ROE CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET 2014-2023 ($ MILLION)
23. INDIA CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET 2014-2023 ($ MILLION)
24. CHINA CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET 2014-2023 ($ MILLION)
25. JAPAN CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET 2014-2023 ($ MILLION)
26. AUSTRALIA CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET 2014-2023 ($ MILLION)
27. ROAPAC CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET 2014-2023 ($ MILLION)
28. LATIN AMERICA CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET 2014-2023 ($ MILLION)
29. MENA CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET 2014-2023 ($ MILLION)

FAQ

How can I purchase a report?
We offer an easy way to purchase any report of your choice from various domains that we offer. You can easily search for your desired reports by simply using the search bar on our website's home page. For multiple purchases, you can add reports to the shopping cart, fill a detail form and check out. We accept payments though authentic and trusted payment gateways which accept all major credit cards.
How safe is to use my credit card? Is my information secure?
We ensure complete safety to all online transactions made by credit cards. We use most secure encryption technology available today for the electronic transactions and all our credit card sales are secured with an SSL technology. Your information is highly secure and confidential.
Can I get a discount?
We send discount offers through email as per your request. In case you would like to receive discounts, please sign up for our newsletter.
I want to buy only a chapter. I don't need complete report.
Yes you can buy your desired chapter/page or the entire report, by just clicking on the table of contents in any report and selecting chapter of your interest. We do have separate pricing for chapters/reports/excel sheets/presentation pages etc.
Can I get reports on my desired topic specially which is not available in your current portfolio?
Do call us or mail us the topic of your preference. Our dedicated team on analysts will prepare a report as per your preference and requirements.
When do I get access to the report(s) that I have purchased?
We will email you your purchased report right after we receive your payment through any of the payment options.
Will I receive any invoice for my purchase?
Yes we will email you invoice/payment confirmation with the order details once we receive your payment.
In what format will the reports be available in?
All the reports will be available in PDF format for download.

Request for Sample


UPCOMING REPORTS

No upcoming reports available under this subcategory.
credit card

CONNECT WITH US

Occams Business Research & Consulting Pvt. Ltd.

Landline: 0731 4042636 

Handheld: +91 9713031393

Email: sales@occamsresearch.com

 

 

Go To Top
viewthroughconversion